| Original language | English (US) |
|---|---|
| Pages (from-to) | 2294-2297 |
| Number of pages | 4 |
| Journal | Journal of the American College of Cardiology |
| Volume | 79 |
| Issue number | 23 |
| DOIs | |
| State | Published - Jun 14 2022 |
Keywords
- diabetes
- heart failure
- risk prediction
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American College of Cardiology, Vol. 79, No. 23, 14.06.2022, p. 2294-2297.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Forecasting Heart Failure Risk in Diabetes
AU - Verma, Subodh
AU - Pandey, Ambarish
AU - Bhatt, Deepak L.
N1 - Funding Information: Dr Verma has received research grants and/or speaker honoraria from Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, EOCI Pharmacomm Ltd, HLS Therapeutics, Janssen, Novartis, Novo Nordisk, Pfizer, PhaseBio, Sanofi, Sun Pharmaceuticals, and the Toronto Knowledge Translation Working Group. Dr Pandey has received grant funding outside the present study from Applied Therapeutics, Gilead Sciences, and the National Institute of Aging GEMSSTAR Grant (1R03AG067960-01); has received honoraria outside of the present study as an advisor/consultant for Tricog Health Inc and Lilly, USA, Rivus, Roche Diagnostics; and has received nonfinancial support from Pfizer and Merck. Dr. Bhatt has been a member of the advisory board for Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, and Stasys; has been on the Board of Directors for Boston VA Research Institute, DRS.LINQ (stock options), the Society of Cardiovascular Patient Care, and TobeSoft; has been the Inaugural Chair of the American Heart Association Quality Oversight Committee; has been a member of Data Monitoring Committees for Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi-Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute, and Rutgers University (for the NIH-funded MINT Trial); has received honoraria from the American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org . Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor-in-Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), and WebMD (CME steering committees), Wiley (steering committee); has received other for Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); has received research funding from Abbott, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, and 89Bio; has received royalties from Elsevier (Editor, Braunwald’s Heart Disease); has been the site co-investigator for Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, and Svelte; has been a trustee for the American College of Cardiology; and has performed unfunded research from FlowCo and Takeda.
PY - 2022/6/14
Y1 - 2022/6/14
KW - diabetes
KW - heart failure
KW - risk prediction
UR - http://www.scopus.com/inward/record.url?scp=85131132873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131132873&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2022.04.011
DO - 10.1016/j.jacc.2022.04.011
M3 - Editorial
C2 - 35680179
AN - SCOPUS:85131132873
SN - 0735-1097
VL - 79
SP - 2294
EP - 2297
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 23
ER -